MaltSci 麦伴科研

Appearance

Popular Reports / Cancer Research

This report is written by MaltSci based on the latest literature and research findings

What is the role of angiogenesis in cancer progression? ​

Abstract ​

Angiogenesis, the physiological process of new blood vessel formation from existing vasculature, plays a pivotal role in cancer progression by providing tumors with the necessary oxygen and nutrients while facilitating the removal of metabolic waste. This review explores the mechanisms of angiogenesis in cancer, particularly the role of Vascular Endothelial Growth Factor (VEGF) and other key angiogenic factors. High levels of VEGF expression correlate with poorer survival outcomes in cancer patients, highlighting its significance in tumor biology. The dynamic interplay between pro-angiogenic and anti-angiogenic signals is influenced by the tumor microenvironment, which supports angiogenesis and contributes to therapeutic resistance. Furthermore, the review discusses the relationship between angiogenesis and metastasis, elucidating how newly formed blood vessels allow cancer cells to intravasate into the bloodstream and disseminate to distant sites. Current and emerging anti-angiogenic therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have shown promise but are often limited by resistance mechanisms. The future of anti-angiogenic therapy lies in combination strategies that integrate these agents with other treatments, such as chemotherapy and immunotherapy, to enhance efficacy. By elucidating the multifaceted role of angiogenesis in cancer progression, this review aims to inform the development of novel therapeutic strategies that can effectively target this critical process, ultimately improving cancer treatment outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Mechanisms of Angiogenesis in Cancer
    • 2.1 The Role of Vascular Endothelial Growth Factor (VEGF)
    • 2.2 Other Key Angiogenic Factors and Pathways
  • 3 The Tumor Microenvironment and Angiogenesis
    • 3.1 Interactions Between Tumor Cells and Endothelial Cells
    • 3.2 The Role of Extracellular Matrix in Angiogenesis
  • 4 Angiogenesis and Metastasis
    • 4.1 Mechanisms Linking Angiogenesis to Tumor Spread
    • 4.2 Case Studies and Evidence from Clinical Research
  • 5 Current and Emerging Anti-Angiogenic Therapies
    • 5.1 Approved Anti-Angiogenic Agents
    • 5.2 Challenges and Limitations of Current Therapies
    • 5.3 Future Directions and Novel Approaches
  • 6 Summary

1 Introduction ​

Angiogenesis, the physiological process through which new blood vessels form from pre-existing ones, is a critical factor in the progression of cancer. It enables tumors to grow and metastasize by providing the necessary oxygen and nutrients, while also facilitating the removal of metabolic waste products. The transition from an avascular state to a vascularized tumor is a hallmark of malignancy, marking a pivotal moment in tumor development that is often associated with increased aggressiveness and poor patient prognosis [1]. The importance of angiogenesis in cancer has led to extensive research into the underlying mechanisms, signaling pathways, and potential therapeutic targets, highlighting its dual role as both a facilitator of tumor growth and a promising avenue for cancer treatment.

The significance of angiogenesis in cancer progression cannot be overstated. Tumors require a robust blood supply to sustain their rapid growth and to disseminate cancer cells throughout the body. The balance between pro-angiogenic factors, such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and various cytokines, and anti-angiogenic signals is crucial in determining the fate of tumor development [2][3]. This dynamic interplay is influenced by the tumor microenvironment, which not only supports angiogenesis but also contributes to the evasion of therapeutic interventions [4]. Understanding these mechanisms is essential for developing more effective cancer therapies that can target the angiogenic process.

Current research has identified several key players in the angiogenic process, including endothelial cells, pericytes, and various extracellular matrix components [5]. These elements work in concert to regulate the formation and stability of new blood vessels. Moreover, the role of tumor-associated cells, such as cancer-associated fibroblasts and immune cells, in modulating angiogenesis has gained increasing attention [6]. The complexities of these interactions underscore the need for a comprehensive understanding of how angiogenesis is regulated within the tumor microenvironment.

In this review, we will systematically explore the mechanisms of angiogenesis in cancer, beginning with the pivotal role of VEGF and other angiogenic factors, followed by a discussion of the tumor microenvironment and its interactions with endothelial cells. We will also examine the relationship between angiogenesis and metastasis, highlighting the mechanisms that link these processes and presenting case studies from clinical research to illustrate their significance. Furthermore, we will analyze current and emerging anti-angiogenic therapies, addressing their challenges and limitations, and consider future directions in the field, including the potential for combination therapies that target both angiogenesis and other aspects of tumor biology [7][8].

By elucidating the multifaceted role of angiogenesis in cancer progression, this review aims to provide insights that can inform the development of novel therapeutic strategies. As the landscape of cancer treatment continues to evolve, a deeper understanding of angiogenesis and its regulatory mechanisms will be crucial in overcoming the challenges posed by tumor heterogeneity and therapeutic resistance [9][10]. Ultimately, our goal is to underscore the importance of angiogenesis in cancer biology and its potential as a therapeutic target, paving the way for more effective and personalized cancer treatment approaches.

2 Mechanisms of Angiogenesis in Cancer ​

2.1 The Role of Vascular Endothelial Growth Factor (VEGF) ​

Angiogenesis, the formation of new blood vessels from existing vasculature, is a critical process in cancer progression, as it facilitates tumor growth, invasion, and metastasis. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and has been shown to play a pivotal role in various cancer types. High expression levels of VEGF are commonly associated with poorer survival outcomes in cancer patients, indicating its significance in tumor biology.

The process of angiogenesis is essential for tumors to achieve a sufficient supply of nutrients and oxygen, which are necessary for continued growth and proliferation. VEGF is secreted by cancer cells and acts as a potent pro-angiogenic factor, promoting neovascularization. This is particularly important as tumors expand beyond a critical mass, necessitating an increased blood supply to sustain their metabolic demands [11].

In the context of cancer therapy, antiangiogenic agents that target VEGF have been developed to inhibit this process. These agents initially result in a reduction of blood flow and vascular permeability within tumors, leading to temporary tumor regression in certain cases, such as renal cancer. However, the effectiveness of these therapies can be limited by the development of resistance. Resistance mechanisms can be classified into de novo resistance, where tumors do not respond to treatment from the outset, and acquired resistance, where tumors initially respond but later progress after a period of treatment [12].

Furthermore, VEGF's influence extends beyond angiogenesis; it also impacts the tumor microenvironment by mediating intercellular interactions. For instance, VEGF has been shown to affect pericyte proliferation and migration, as well as to mediate interactions between tumor-associated macrophages and cancer cells. This interplay can lead to immunosuppression and promote epithelial-mesenchymal transition (EMT), further enhancing tumor aggressiveness [13].

Overall, the role of VEGF in angiogenesis and its broader implications in cancer progression underscore the complexity of tumor biology. Understanding these mechanisms is crucial for the development of effective therapeutic strategies, particularly in optimizing the use of anti-VEGF therapies and overcoming resistance [14].

In conclusion, angiogenesis is a fundamental process in cancer progression, with VEGF serving as a central mediator. The interplay between angiogenesis, tumor microenvironment, and therapeutic resistance highlights the need for continued research to improve cancer treatment outcomes.

2.2 Other Key Angiogenic Factors and Pathways ​

Angiogenesis, the process of forming new blood vessels from pre-existing ones, plays a critical role in cancer progression. This process is essential for tumor growth and metastasis, as tumors require a blood supply to deliver nutrients and oxygen while removing waste products. The mechanisms of angiogenesis in cancer involve a complex interplay of various angiogenic factors, signaling pathways, and cellular interactions.

In solid tumors, angiogenesis is initiated when tumor cells release pro-angiogenic factors, which stimulate surrounding endothelial cells (ECs) to proliferate and migrate, forming new blood vessels. This process is particularly vital during the transition from the avascular phase, where tumors are small and rely on passive diffusion for nutrient supply, to the vascular phase, where rapid tumor growth and invasiveness occur. The shift to a vascularized state is characterized by the secretion of angiogenic factors such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and Angiopoietins, which collectively enhance endothelial cell proliferation, migration, and survival (Madu et al. 2020; Gasparini 1995).

The regulation of angiogenesis is not solely dependent on pro-angiogenic factors; it is also influenced by angiogenic inhibitors, which maintain a balance within the tumor microenvironment. In normal tissues, inhibitory pathways predominate, whereas in invasive cancers, the balance shifts towards angiogenic activity. The interplay between these factors is governed by various biochemical and genetic mechanisms, highlighting the importance of understanding the angiogenic switch in cancer therapy (Gupta and Qin 2003; Lorenc et al. 2024).

Several key pathways and factors contribute to the angiogenic process. The VEGF/VEGFR signaling pathway is one of the most well-studied, as it plays a pivotal role in promoting endothelial cell proliferation and survival. Anti-angiogenic therapies targeting this pathway have been developed, although challenges such as resistance mechanisms and the complexity of angiogenic signaling have been noted (Harry and Ormiston 2021; Elayat and Selim 2024).

In addition to VEGF, other signaling pathways such as Notch, Bone Morphogenetic Protein (BMP), and Sonic Hedgehog are being explored for their roles in regulating tumor angiogenesis. These pathways interact with the tumor microenvironment and influence the behavior of endothelial cells, thereby impacting tumor growth and metastasis (Cazzato et al. 2024). Furthermore, the role of cytokines and chemokines in modulating angiogenesis within the tumor context has been recognized, with these factors either promoting or inhibiting the angiogenic process depending on their concentrations and the specific tumor environment (Geindreau et al. 2022).

Understanding the mechanisms of angiogenesis in cancer progression is crucial for developing effective therapeutic strategies. By targeting the angiogenic factors and pathways involved, researchers aim to inhibit tumor growth and improve patient outcomes. Current therapeutic approaches are increasingly focusing on combination strategies that integrate anti-angiogenic agents with other treatments such as chemotherapy and immunotherapy to enhance their efficacy and overcome resistance (Aspriţoiu et al. 2021; Miyake et al. 2015).

In summary, angiogenesis is a fundamental process in cancer progression, driven by a network of pro- and anti-angiogenic factors and signaling pathways. Continued research into these mechanisms holds promise for the development of innovative therapies aimed at disrupting tumor vascularization and improving cancer treatment outcomes.

3 The Tumor Microenvironment and Angiogenesis ​

3.1 Interactions Between Tumor Cells and Endothelial Cells ​

Angiogenesis, the process of forming new blood vessels from pre-existing ones, plays a pivotal role in cancer progression by facilitating tumor growth and metastasis. It is crucial for providing the necessary oxygen and nutrients to the rapidly proliferating tumor cells, thereby supporting their survival and expansion. The interplay between tumor cells and endothelial cells is central to this process, as it involves a complex network of signaling pathways and molecular interactions.

Tumor cells secrete various pro-angiogenic factors, such as Vascular Endothelial Growth Factor (VEGF), which directly stimulate endothelial cell proliferation, migration, and new blood vessel formation. These interactions are not merely one-sided; endothelial cells also respond to signals from the tumor microenvironment, creating a dynamic relationship that promotes angiogenesis. For instance, tumor-derived cytokines and chemokines can modulate endothelial cell behavior, enhancing their capacity to form new vascular structures [2].

The significance of angiogenesis in cancer is underscored by its role in enabling not only the initial growth of tumors but also their ability to metastasize. Angiogenesis is necessary for the development of distant metastases, as it allows cancer cells to intravasate into the bloodstream and disseminate to other organs. Moreover, the formation of new blood vessels can also create a supportive niche for tumor cells, helping them evade immune surveillance and resist therapeutic interventions [1].

The balance between pro-angiogenic and anti-angiogenic factors is critical. In normal tissues, angiogenesis is tightly regulated, often favoring inhibitory pathways. However, in the tumor microenvironment, this balance is disrupted, leading to enhanced angiogenic activity that correlates with tumor aggressiveness and poor prognosis [1]. For example, studies have shown that the degree of vascularization in primary invasive cancers, such as breast cancer, is heterogeneous and directly correlates with patient outcomes [1].

Moreover, the tumor microenvironment is not just a passive backdrop; it actively influences angiogenesis through the recruitment of various cell types, including cancer-associated fibroblasts and immune cells, which secrete additional angiogenic factors [3]. This intricate interplay suggests that targeting the interactions between tumor cells and endothelial cells could represent a promising therapeutic strategy. Anti-angiogenic therapies aim to disrupt these interactions, thereby inhibiting tumor growth and metastasis. For instance, agents like bevacizumab, which targets VEGF, have been utilized in clinical settings to hinder angiogenesis in various cancers [15].

In conclusion, angiogenesis is a fundamental process in cancer progression, intricately linked to the interactions between tumor cells and endothelial cells. This relationship not only supports tumor growth but also facilitates metastasis, making it a critical target for therapeutic intervention in cancer treatment. Understanding the molecular mechanisms governing these interactions could pave the way for novel anti-cancer strategies aimed at disrupting the pro-angiogenic signals within the tumor microenvironment.

3.2 The Role of Extracellular Matrix in Angiogenesis ​

Angiogenesis, the process of new blood vessel formation from pre-existing vasculature, is a crucial component of cancer progression. It provides tumors with the necessary oxygen and nutrients for growth and facilitates the removal of metabolic waste. This process is particularly significant in the context of solid tumors, where the transition from an avascular to a vascular phase is associated with rapid tumor growth and increased local invasiveness [1].

The tumor microenvironment (TME) plays a vital role in regulating angiogenesis. Within the TME, various cellular components, including cancer-associated fibroblasts, macrophages, and endothelial cells, interact to modulate angiogenic processes. Tumor cells secrete pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), which promote the formation of new blood vessels. These factors often work in conjunction with reactive oxygen species (ROS) produced by the tumor cells, which can activate both VEGF-dependent and non-VEGF-dependent pathways of angiogenesis [16].

The extracellular matrix (ECM) is a critical component of the TME that influences angiogenesis. The ECM provides structural support to tissues and regulates various cellular functions through biochemical signals. In cancer, the ECM undergoes significant remodeling, which can enhance angiogenic signaling. Matrix metalloproteinases (MMPs), for instance, are enzymes that degrade ECM components and facilitate the release of angiogenic factors, thereby promoting vascularization [17]. Additionally, the composition and mechanical properties of the ECM can affect endothelial cell behavior, influencing their migration, proliferation, and tube formation, all of which are essential for angiogenesis [7].

Furthermore, the balance between pro-angiogenic and anti-angiogenic factors within the TME is critical for determining the extent of angiogenesis. In normal tissues, the inhibitory pathways predominate, but in tumors, the overexpression of angiogenic factors leads to a net increase in vascularization. This dysregulation is often a result of genetic and epigenetic alterations in the tumor cells, which can affect the expression of angiogenic mediators [5].

Angiogenesis is not only essential for primary tumor growth but also plays a significant role in metastasis. The newly formed blood vessels can serve as conduits for tumor cells to disseminate to distant sites, where they can establish secondary tumors. This process is influenced by various signaling pathways and the presence of specific cell types within the TME, which can either promote or inhibit angiogenesis [3].

In summary, angiogenesis is a fundamental aspect of cancer progression, intricately linked to the tumor microenvironment and the extracellular matrix. The dynamic interplay between tumor cells, the ECM, and various cellular components of the TME facilitates the angiogenic process, thereby supporting tumor growth and metastasis. Understanding these interactions is crucial for developing effective anti-angiogenic therapies aimed at inhibiting tumor progression and improving patient outcomes [18][19].

4 Angiogenesis and Metastasis ​

4.1 Mechanisms Linking Angiogenesis to Tumor Spread ​

Angiogenesis plays a critical role in cancer progression, particularly in facilitating tumor growth and metastasis. It is the process through which new blood vessels form from pre-existing ones, ensuring that tumors receive the necessary nutrients and oxygen to thrive. This is especially vital for tumors as they grow beyond a certain size, where diffusion alone cannot meet their metabolic demands. The formation of new blood vessels also provides a route for cancer cells to enter the bloodstream, promoting metastasis.

In the context of tumor progression, several pro-angiogenic factors are involved. Vascular endothelial growth factor (VEGF), for instance, is recognized as a primary mitogen for vascular endothelial cells, stimulating their proliferation and survival, thus playing a central role in the angiogenic process [20]. Other factors such as interleukin-8 (IL-8), platelet-derived endothelial cell growth factor (PDGF), and fibroblast growth factor (FGF) also contribute significantly to angiogenesis and have been linked to metastasis [21]. The activation of these angiogenic pathways not only supports the growth of primary tumors but also aids in the establishment of metastatic lesions.

The tumor microenvironment (TME) further complicates the interplay between angiogenesis and metastasis. Cells within the TME, including cancer-associated fibroblasts, mast cells, and macrophages, can secrete various factors that enhance angiogenesis and influence tumor behavior [3]. This dynamic interaction highlights the complexity of the tumor ecosystem and underscores the importance of targeting both tumor cells and their microenvironment in therapeutic strategies.

Moreover, the relationship between angiogenesis and metastasis is reciprocal. As tumors metastasize, they often induce angiogenesis at distant sites, facilitating their survival and growth in new environments [22]. For instance, tumors can release signals that not only attract new blood vessels but also stimulate the growth of nerve fibers, creating a supportive network for tumor cell migration and colonization [22].

Challenges arise in the development of anti-angiogenic therapies, as tumors can develop resistance mechanisms that activate alternative angiogenic pathways [3]. This has led to the exploration of combination therapies that integrate anti-angiogenic agents with immunotherapies to enhance treatment efficacy and overcome resistance [3].

In summary, angiogenesis is a pivotal process in cancer progression, facilitating tumor growth and metastasis through the provision of nutrients and the creation of pathways for tumor cells to spread. Understanding the mechanisms that link angiogenesis to tumor spread is essential for developing effective therapeutic interventions aimed at controlling cancer progression.

4.2 Case Studies and Evidence from Clinical Research ​

Angiogenesis, the process of new blood vessel formation, plays a crucial role in cancer progression, particularly in the context of metastasis. The transformation from an avascular to a vascular state is a pivotal event in tumor development, facilitating not only primary tumor growth but also the potential for metastasis. Several studies have demonstrated the significance of angiogenesis in various types of cancer, including breast cancer, melanoma, liver metastases, and gastric cancer.

In breast cancer, angiogenesis is integral to tumor progression and metastasis. The angiogenic activity is determined by the balance between pro-angiogenic factors and their inhibitors, which is regulated by complex biochemical and genetic mechanisms. Notably, the degree of vascularization in primary invasive breast tumors has been shown to correlate with patient prognosis, suggesting that enhanced angiogenesis may be indicative of aggressive disease and poor outcomes (Gasparini 1995) [1].

Similarly, in melanoma, a highly aggressive form of skin cancer, angiogenesis is essential for tumor progression. Pro-angiogenic factors such as VEGF and FGF-2 contribute to the development of the tumor microenvironment, which is critical for melanoma metastasis. The interplay between tumor cells and the surrounding stroma, including cancer-associated fibroblasts and macrophages, further modulates angiogenesis, complicating therapeutic strategies. The emergence of resistance to anti-angiogenic therapies underscores the necessity for innovative combinations with immunotherapies to enhance treatment efficacy (Cazzato et al. 2024) [3].

In the context of metastasis, the process of angiogenesis is vital at multiple stages, from the initial invasion of tumor cells into the vasculature to the establishment of metastatic sites. Successful metastasis formation requires angiogenesis at both the primary tumor site and the metastatic site. For instance, in liver metastasis, factors such as vascular endothelial growth factor (VEGF) and interleukin-8 have been implicated in promoting angiogenesis, thereby facilitating the survival and growth of metastatic lesions (Takeda et al. 2002) [21]. The establishment of a new vascular network allows for nutrient supply and waste removal, which are essential for the growth of metastatic tumors.

Moreover, early-stage gastric cancer has shown a significant correlation between angiogenesis and lymph node metastasis. A study indicated that higher microvessel counts in tumors were associated with lymphatic invasion and metastasis, positioning angiogenesis as an independent factor influencing metastatic potential (Xiangming et al. 1998) [23].

In summary, angiogenesis is a critical facilitator of cancer progression and metastasis. It enables tumor growth and the spread of cancer cells by providing necessary resources and a conducive environment for survival and proliferation. Understanding the mechanisms of angiogenesis not only enhances the knowledge of cancer biology but also highlights potential therapeutic targets, as anti-angiogenic strategies are being explored to improve clinical outcomes in cancer patients.

5 Current and Emerging Anti-Angiogenic Therapies ​

5.1 Approved Anti-Angiogenic Agents ​

Angiogenesis plays a crucial role in cancer progression, serving as a fundamental process that facilitates tumor growth and metastasis. It involves the formation of new blood vessels from pre-existing ones, which is essential for providing oxygen and nutrients to proliferating cancer cells. The vascular endothelial growth factor (VEGF) pathway is a key mediator of this process, with numerous pro-angiogenic factors, such as VEGF, angiopoietin (Ang), and hypoxia-inducible factor (HIF-1), being upregulated in hypoxic tumor microenvironments[24].

In various malignancies, including melanoma, breast cancer, pancreatic cancer, and non-Hodgkin lymphomas, the interplay between angiogenesis and the tumor microenvironment (TME) is intricate. For instance, in melanoma, pro-angiogenic factors like VEGF, PlGF, and FGF-2 contribute to tumor metastasis and progression, while cells within the TME, such as cancer-associated fibroblasts and macrophages, further influence angiogenesis[3]. In breast cancer, the inhibition of angiogenesis has emerged as a promising therapeutic strategy, highlighting the importance of endogenous stimulators and inhibitors in modulating this process[25].

Current and emerging anti-angiogenic therapies aim to disrupt the angiogenic processes that tumors exploit for growth. These therapies can be classified into monoclonal antibodies targeting VEGF or its receptors, tyrosine kinase inhibitors, and other agents that affect the angiogenic signaling pathways. Notably, anti-angiogenic therapies have demonstrated the potential to enhance the efficacy of traditional chemotherapeutic agents by overcoming some forms of drug resistance[26].

Approved anti-angiogenic agents, such as bevacizumab and aflibercept, have shown survival benefits in patients with colorectal cancer, among other malignancies[6]. However, the efficacy of these therapies is often limited by challenges such as drug resistance and the tumor's ability to activate alternative angiogenic pathways. This has led to the exploration of combination therapies that integrate anti-angiogenic agents with immunotherapies or other treatment modalities to improve outcomes for patients[3].

In summary, angiogenesis is integral to cancer progression, and targeting this process through anti-angiogenic therapies presents a viable strategy for cancer treatment. However, ongoing research is necessary to develop innovative approaches that can effectively address the complexities of tumor angiogenesis and enhance therapeutic efficacy[27].

5.2 Challenges and Limitations of Current Therapies ​

Angiogenesis plays a crucial role in cancer progression by providing tumors with the necessary blood supply for growth and metastasis. It is characterized by the formation of new blood vessels from pre-existing ones, a process that is heavily influenced by various pro-angiogenic factors such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF), fibroblast growth factor 2 (FGF-2), interleukin-8 (IL-8), angiopoietins (Ang), transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), integrins, matrix metalloproteinases (MMPs), and platelet-activating factor (PAF) [3]. These factors not only modulate angiogenesis but also contribute to the metastatic potential of tumors.

In breast cancer, the link between angiogenesis and tumor progression has been recognized for over 25 years. The therapeutic strategy focusing on inhibiting angiogenesis has gained attention due to its potential to treat cancer without the cytotoxic effects associated with conventional chemotherapy [25]. Anti-angiogenic therapies aim to disrupt the blood supply to tumors, thereby hindering their growth and spread. However, the efficacy of these therapies can be influenced by the tumor microenvironment (TME), which includes cancer-associated fibroblasts, mast cells, and macrophages that can enhance angiogenesis and tumor progression [3].

Current and emerging anti-angiogenic therapies target various components of the angiogenic process. For instance, inhibitors of the VEGF pathway, such as monoclonal antibodies and tyrosine kinase inhibitors, have been developed to disrupt the signaling that promotes angiogenesis [28]. Despite the initial promise shown in preclinical studies, clinical outcomes have been less favorable, with many therapies failing to demonstrate significant survival benefits in patients [28].

Challenges and limitations of current anti-angiogenic therapies include the development of drug resistance and the activation of alternative angiogenic pathways by tumors. For example, while anti-angiogenic therapies can reduce tumor blood supply, they may also lead to a compensatory increase in other pathways that promote angiogenesis [3]. Additionally, the identification of biomarkers to predict treatment response is crucial for personalizing therapies, as the effectiveness of anti-angiogenic agents can vary significantly among patients [3].

Moreover, the paradox of anti-angiogenic therapy lies in its dual effect: while it aims to block the vascular supply to tumors, it can simultaneously reduce the delivery of therapeutic agents, complicating treatment strategies [29]. As such, rational combinations of anti-angiogenic agents with immunotherapies are being explored to enhance efficacy and overcome resistance [3].

In conclusion, angiogenesis is a pivotal factor in cancer progression, influencing both tumor growth and metastasis. Although anti-angiogenic therapies represent a promising avenue for cancer treatment, significant challenges remain in optimizing their effectiveness and managing resistance, necessitating ongoing research and innovative therapeutic strategies.

5.3 Future Directions and Novel Approaches ​

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a pivotal role in cancer progression. It is essential for tumor growth, invasion, and metastasis, as tumors require an adequate blood supply to sustain their rapid proliferation and facilitate the dissemination of cancer cells to distant sites. The "angiogenic switch" is a critical event in this process, marked by an imbalance between pro- and anti-angiogenic factors, which transitions the tumor from a prevascular state to a vascularized tumor capable of malignant progression[30].

Current anti-angiogenic therapies primarily target key molecular players involved in angiogenesis, such as vascular endothelial growth factor (VEGF) and its receptors. Monoclonal antibodies, like bevacizumab and ramucirumab, as well as receptor tyrosine kinase inhibitors (TKIs) such as sorafenib and sunitinib, have shown efficacy in various malignancies[31]. These agents aim to inhibit the signaling pathways that promote angiogenesis, thereby disrupting the tumor's ability to grow and metastasize. However, the clinical benefits of these therapies have been limited by issues such as adverse effects, acquired drug resistance, and the lack of validated biomarkers to predict treatment responses[32].

Emerging strategies in anti-angiogenic therapy include the application of nanotechnology and immunotherapy. Nanoparticles designed to deliver anti-angiogenic agents directly to the tumor microenvironment can enhance therapeutic efficacy while minimizing systemic toxicity[33]. Additionally, the integration of immunotherapy with anti-angiogenic approaches is being explored to leverage the immune system's capacity to combat tumors while simultaneously inhibiting angiogenesis[34].

Future directions in this field focus on a deeper understanding of the tumor microenvironment and the heterogeneity of endothelial cells within tumors. Single-cell sequencing technologies are being utilized to unravel the complexities of endothelial cell interactions with stromal and immune cells, which could provide insights into novel therapeutic targets and combination strategies[34]. Furthermore, the identification of new biomarkers for patient stratification and the development of combination therapies that address the limitations of current anti-angiogenic treatments are crucial for improving clinical outcomes[27].

In summary, angiogenesis is a critical process in cancer progression, and while current anti-angiogenic therapies have made significant strides, ongoing research into novel approaches and a better understanding of tumor biology are essential for enhancing the efficacy of these treatments and ultimately improving patient survival.

6 Conclusion ​

Angiogenesis is a fundamental process in cancer progression, serving as a crucial mechanism that facilitates tumor growth and metastasis. The review highlights several key findings regarding the intricate relationship between angiogenesis and tumor biology. Firstly, the role of Vascular Endothelial Growth Factor (VEGF) as a primary mediator of angiogenesis is underscored, with its expression correlating with poor patient outcomes across various cancer types. Secondly, the interplay between pro-angiogenic and anti-angiogenic factors within the tumor microenvironment is critical, as it determines the balance that favors tumor vascularization and aggressiveness. The review also emphasizes the complexity of tumor-associated cells, including cancer-associated fibroblasts and immune cells, which further modulate angiogenesis and contribute to therapeutic resistance. Current anti-angiogenic therapies, while promising, face significant challenges, including the development of resistance and the activation of alternative pathways. Future research should focus on innovative strategies, such as combination therapies that integrate anti-angiogenic agents with immunotherapy and a deeper understanding of the tumor microenvironment. By addressing these challenges and exploring novel approaches, the potential for more effective cancer treatments that target angiogenesis can be realized, ultimately improving patient outcomes and survival rates.

References ​

  • [1] G Gasparini. Biological and clinical role of angiogenesis in breast cancer.. Breast cancer research and treatment(IF=3.0). 1995. PMID:8534859. DOI: 10.1007/BF00666032.
  • [2] Mannon Geindreau;Mélanie Bruchard;Frédérique Vegran. Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context.. Cancers(IF=4.4). 2022. PMID:35626056. DOI: 10.3390/cancers14102446.
  • [3] Gerardo Cazzato;Giuseppe Ingravallo;Domenico Ribatti. Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression.. Cancers(IF=4.4). 2024. PMID:38791873. DOI: 10.3390/cancers16101794.
  • [4] Victor Oginga Oria;Janine Terra Erler. Tumor Angiocrine Signaling: Novel Targeting Opportunity in Cancer.. Cells(IF=5.2). 2023. PMID:37887354. DOI: 10.3390/cells12202510.
  • [5] S P Balasubramanian;N J Brown;M W R Reed. Role of genetic polymorphisms in tumour angiogenesis.. British journal of cancer(IF=6.8). 2002. PMID:12402142. DOI: 10.1038/sj.bjc.6600625.
  • [6] Renata Ferrarotto;Paulo M Hoff. Antiangiogenic drugs for colorectal cancer: exploring new possibilities.. Clinical colorectal cancer(IF=3.2). 2013. PMID:22763196. DOI: .
  • [7] M Miyake;S Goodison;A Lawton;E Gomes-Giacoia;C J Rosser. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.. Oncogene(IF=7.3). 2015. PMID:24561529. DOI: 10.1038/onc.2014.2.
  • [8] Joyce Liu;Ursula A Matulonis. Anti-angiogenic agents in ovarian cancer: dawn of a new era?. Current oncology reports(IF=5.0). 2011. PMID:21993845. DOI: 10.1007/s11912-011-0194-8.
  • [9] Arianna Filippelli;Cinzia Del Gaudio;Vittoria Simonis;Valerio Ciccone;Andrea Spini;Sandra Donnini. Scoping Review on Platelets and Tumor Angiogenesis: Do We Need More Evidence or Better Analysis?. International journal of molecular sciences(IF=4.9). 2022. PMID:36362186. DOI: 10.3390/ijms232113401.
  • [10] Debashree Basudhar;Veena Somasundaram;Graciele Almeida de Oliveira;Aparna Kesarwala;Julie L Heinecke;Robert Y Cheng;Sharon A Glynn;Stefan Ambs;David A Wink;Lisa A Ridnour. Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.. Antioxidants & redox signaling(IF=6.1). 2017. PMID:27464521. DOI: 10.1089/ars.2016.6813.
  • [11] J P Crew. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer.. European urology(IF=25.2). 1999. PMID:9933788. DOI: 10.1159/000019811.
  • [12] Faisal Azam;Shaveta Mehta;Adrian L Harris. Mechanisms of resistance to antiangiogenesis therapy.. European journal of cancer (Oxford, England : 1990)(IF=7.1). 2010. PMID:20236818. DOI: 10.1016/j.ejca.2010.02.020.
  • [13] Pallab Shaw;Shailendra Kumar Dhar Dwivedi;Resham Bhattacharya;Priyabrata Mukherjee;Geeta Rao. VEGF signaling: Role in angiogenesis and beyond.. Biochimica et biophysica acta. Reviews on cancer(IF=8.3). 2024. PMID:38280470. DOI: 10.1016/j.bbcan.2024.189079.
  • [14] Irina Sousa Moreira;Pedro Alexandrino Fernandes;Maria João Ramos. Vascular endothelial growth factor (VEGF) inhibition--a critical review.. Anti-cancer agents in medicinal chemistry(IF=3.0). 2007. PMID:17348829. DOI: 10.2174/187152007780058687.
  • [15] Ana Elisa Lohmann;Stephen Chia. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?. Current treatment options in oncology(IF=4.7). 2012. PMID:22350496. DOI: 10.1007/s11864-012-0181-9.
  • [16] B Mdkhana;S Goel;M A Saleh;R Siddiqui;N A Khan;A B Elmoselhi. Role of oxidative stress in angiogenesis and the therapeutic potential of antioxidants in breast cancer.. European review for medical and pharmacological sciences(IF=3.3). 2022. PMID:35856359. DOI: 10.26355/eurrev_202207_29192.
  • [17] Madeleine M Handsley;Dylan R Edwards. Metalloproteinases and their inhibitors in tumor angiogenesis.. International journal of cancer(IF=4.7). 2005. PMID:15729716. DOI: 10.1002/ijc.20945.
  • [18] Gang Li;Dengqin He;Xiaojia Cai;Wen Guan;Yali Zhang;Jia-Qiang Wu;Hongliang Yao. Advances in the development of phosphodiesterase-4 inhibitors.. European journal of medicinal chemistry(IF=5.9). 2023. PMID:36809706. DOI: 10.1016/j.ejmech.2023.115195.
  • [19] Qinwei An;Wenqi Xiong;Feng Hu;Yikang Yu;Pengfei Lv;Siqi Hu;Xuetao Gan;Xiaobo He;Jianlin Zhao;Shengjun Yuan. Direct growth of single-chiral-angle tungsten disulfide nanotubes using gold nanoparticle catalysts.. Nature materials(IF=38.5). 2024. PMID:37443381. DOI: 10.1038/s41563-023-01590-5.
  • [20] Aleksandra Sobczyńska-Rak;Beata Żylińska;Beata Nowicka;Eryk Rak;Tomasz Rzepka. Role and Mechanisms of Angiogenesis in Tumours.. Biology(IF=3.5). 2025. PMID:40723317. DOI: 10.3390/biology14070756.
  • [21] Akihiko Takeda;Oliver Stoeltzing;Syed A Ahmad;Niels Reinmuth;Wenbiao Liu;Alexander Parikh;Fan Fan;Morihisa Akagi;Lee M Ellis. Role of angiogenesis in the development and growth of liver metastasis.. Annals of surgical oncology(IF=3.5). 2002. PMID:12167573. DOI: 10.1007/BF02574475.
  • [22] Zodwa Dlamini;Richard Khanyile;Thulo Molefi;Botle Precious Damane;David Owen Bates;Rodney Hull. Genomic Interplay between Neoneurogenesis and Neoangiogenesis in Carcinogenesis: Therapeutic Interventions.. Cancers(IF=4.4). 2023. PMID:36980690. DOI: 10.3390/cancers15061805.
  • [23] C Xiangming;S Hokita;S Natsugoe;G Tanabe;M Baba;S Takao;K Kuroshima;T Aikou. Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer.. Annals of surgical oncology(IF=3.5). 1998. PMID:9831105. DOI: 10.1007/BF02303826.
  • [24] Shiyu Qi;Shoulong Deng;Zhengxing Lian;Kun Yu. Novel Drugs with High Efficacy against Tumor Angiogenesis.. International journal of molecular sciences(IF=4.9). 2022. PMID:35805939. DOI: 10.3390/ijms23136934.
  • [25] I Wu;M A Moses. Angiogenic molecules and mechanisms in breast cancer.. Current oncology reports(IF=5.0). 2000. PMID:11122894. DOI: 10.1007/s11912-000-0111-z.
  • [26] L Rosen. Antiangiogenic strategies and agents in clinical trials.. The oncologist(IF=4.2). 2000. PMID:10804087. DOI: 10.1634/theoncologist.5-suppl_1-20.
  • [27] Xueru Liu;Juan Zhang;Ting Yi;Hui Li;Xing Tang;Dan Liu;Daichao Wu;Yukun Li. Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.. Biomarker research(IF=11.5). 2025. PMID:40251641. DOI: 10.1186/s40364-025-00779-x.
  • [28] Christopher Montemagno;Gilles Pagès. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.. Frontiers in cell and developmental biology(IF=4.3). 2020. PMID:32775327. DOI: 10.3389/fcell.2020.00584.
  • [29] Tiziana Annese;Roberto Tamma;Simona Ruggieri;Domenico Ribatti. Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies.. Cancers(IF=4.4). 2019. PMID:30889903. DOI: 10.3390/cancers11030381.
  • [30] Anchal Pathak;Ajay Kumar Pal;Subhadeep Roy;Mukesh Nandave;Keerti Jain. Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.. Stem cells international(IF=3.3). 2024. PMID:38213742. DOI: 10.1155/2024/9077926.
  • [31] Biagio Ricciuti;Jennifer Foglietta;Vanessa Bianconi;Amirhossein Sahebkar;Matteo Pirro. Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy.. Seminars in cancer biology(IF=15.7). 2019. PMID:29128510. DOI: 10.1016/j.semcancer.2017.11.005.
  • [32] Zhen-Ling Liu;Huan-Huan Chen;Li-Li Zheng;Li-Ping Sun;Lei Shi. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.. Signal transduction and targeted therapy(IF=52.7). 2023. PMID:37169756. DOI: 10.1038/s41392-023-01460-1.
  • [33] Sudip Mukherjee;Chitta Ranjan Patra. Therapeutic application of anti-angiogenic nanomaterials in cancers.. Nanoscale(IF=5.1). 2016. PMID:27067119. DOI: 10.1039/c5nr07887c.
  • [34] Shuaixi Yang;Yingshuai Fang;Yangcheng Ma;Fuqi Wang;Yuhang Wang;Jiachi Jia;Yabing Yang;Weipeng Sun;Quanbo Zhou;Zhen Li. Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.. Clinical and translational medicine(IF=6.8). 2025. PMID:40268524. DOI: 10.1002/ctm2.70313.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Angiogenesis · Cancer Progression · Vascular Endothelial Growth Factor

© 2025 MaltSci